Co-authors explain why ACS strengthened prostate cancer screening guidelines

New evidence, technologies “opened the door to a screening process that can mitigate harm while preserving benefit”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Ruth Etzioni, PhD
Professor, Biostatistics Program, Public Health Sciences Division, Rosalie and Harold Rea Brown Endowed Chair, Member, Translational Data Science Integrated Research Center, Affiliate Investigator, Clinical Research Division, Fred Hutch Cancer Center
Richard Hoffman, MD
General internist, Professor Emeritus of Medicine, University of Iowa
Andrew Wolf, MD
General internist, Professor Emeritus of Medicine, UVA School of Medicine
Table of Contents

YOU MAY BE INTERESTED IN

 For nearly 30 years, the American Cancer Society’s prostate cancer screening guidelines have advised men to discuss prostate-specific antigen, or PSA, testing with a clinician and weigh potential benefits and harms, rather than treat screening as an unquestioned routine. This “informed decision-making” recommendation was consistent with guidelines from all major professional organizations in the United States, Canada, and Europe. 
At the recommended regimen, 73% of patients receiving a pasritamig and JNJ-9401 combination, two bispecific antibodies designed to work together to drive the body’s immune response against advanced prostate cancer, achieved reductions of at least 50% in prostate-specific antigen, according to the results of a first-in-human phase I study. 
An international phase III clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor—plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.
Ruth Etzioni, PhD
Professor, Biostatistics Program, Public Health Sciences Division, Rosalie and Harold Rea Brown Endowed Chair, Member, Translational Data Science Integrated Research Center, Affiliate Investigator, Clinical Research Division, Fred Hutch Cancer Center
Richard Hoffman, MD
General internist, Professor Emeritus of Medicine, University of Iowa
Andrew Wolf, MD
General internist, Professor Emeritus of Medicine, UVA School of Medicine

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login